tbuckley/cabot-search huggingface dataset:
Variation in rates of caesarean section among English NHS trusts after accounting for maternal and clinical risk: cross sectional study
Journal: BMJ (2010)

Objective To determine whether the variation in unadjusted rates of caesarean section derived from routine data in NHS trusts in England can be explained by maternal characteristics and clinical risk factors.Design A cross sectional analysis using routinely collected hospital episode statistics was performed.A multiple logistic regression model was used to estimate the likelihood of women having a caesarean section given their maternal characteristics (age, ethnicity, parity, socioeconomic deprivation) and clinical risk factors (previous caesarean section, breech presentation, fetal distress).Adjusted rates of caesarean section for each NHS trust were produced from this model.Setting 146 English NHS trusts.Population Women aged between 15 and 44 years with a singleton birth between 1 January and 31 December 2008.Main outcome measure Rate of caesarean sections per 100 births (live or stillborn).Results Among 620 604 singleton births, 147 726 (23.8%) were delivered by caesarean section.Women were more likely to have a caesarean section if they had had one previously (70.8%) or had a baby with breech presentation (89.8%).Unadjusted rates of caesarean section among the NHS trusts ranged from 13.6% to 31.9%.Trusts differed in their patient populations, but adjusted rates still ranged from 14.9% to 32.1%.Rates of emergency caesarean section varied between trusts more than rates of elective caesarean section.Conclusion Characteristics of women delivering at NHS trusts differ, and comparing unadjusted rates of caesarean section should be avoided.Adjusted rates of caesarean section still vary considerably and attempts to reduce this variation should examine issues linked to emergency caesarean section.
Research funding, myocardial infarction triggers among areas of concern addressed at AHA forum
Authors: P. Gunby
Journal: JAMA (1996)

CARDIOVASCULAR disease research, says the president of the American Heart Association (AHA), poses a paradox. Heart-related disease, says AHA President Jan L. Breslow, MD, seems to be slipping from the attention of the American public. Or, if Americans do pause to ponder cardiovascular disease, many are coming to regard it as an elderly person's malady and perhaps even a good way to die. What's more, politicians and some scientists in policymaking positions now are underfunding cardiovascular research, Breslow contends. He says this may be because—in seeking support— scientists have oversold the success of surgery, drugs, and increased knowledge of cardiovascular disease processes that have improved patient care and outcomes. Now, says Breslow, who is Leonhardt Professor, Rockefeller University, New York, NY, it's time to stop broadcasting those successes and emphasize that heart disease still is the No. 1 killer of people in this country and stroke is No. 3. Also
Prolapsed Cord
Authors: S. A. Seligman
Journal: BMJ (1960)

SUBACUTE COMBINED DEGENERATIONMBpIcAL OURNAk gastrectomy, as long as seven years may elapse before development of megaloblastic anaemia.It took 10 years before evidence of frank vitamin-B12 deficiency occurred in our patient, in whom some secretion of intrinsic factor was almost certainly present immediately after the operation.The time interval is of the same order as in the two cases described by Rowlands and Simpson (1932), the symptoms in these cases developing 6 and 15 years after the operation.Summary A case is described of subacute combined degeneration of the cord after partial gastrectomy for gastric ulceration in a man aged 32.Evidence is presented to show that the vitamin-B12 deficiency was consequent upon impaired secretion of intrinsic factor owing to the presence of chronic atrophic gastritis.Attention is drawn to the higher incidence of atrophic gastritis and malabsorption of vitamin B,2 after partial gastrectomy for gastric ulceration as compared with that following this operation for duodenal ulceration.We thank Dr. R.
WASHINGTON NEWS
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.04-29 Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
Authors: J. Sun, Q. Yang, M. Chen, J. Gu, L. Zheng, Y. Yu, F. Li, L. Zhang, K. Niu
Journal: Journal of Thoracic Oncology (2019)
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)
Authors: Ulrik Ralfkiaer, Peter H. Hagedorn, Nannie Bangsgaard, Marianne B. Løvendorf, Charlotte B. Ahler, Lars Svensson, Katharina L. Kopp, Marie T. Vennegaard, Britt Lauenborg, John R. Zibert, Thorbjørn Krejsgaard, Charlotte M. Bonefeld, Rolf Søkilde, Lise M. Gjerdrum, Tord Labuda, Anne-Merete Mathiesen, Kirsten Grønbæk, Mariusz A. Wasik, Malgorzata Sokolowska-Wojdylo, Catherine Queille-Roussel, Robert Gniadecki, Elisabeth Ralfkiaer, Carsten Geisler, Thomas Litman, Anders Woetmann, Christian Glue, Mads A. Røpke, Lone Skov, Niels Odum
Journal: Blood (2011)
Neurulation
Authors: Saurabh Sinha
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Omission in Funding/Support Section
Journal: JAMA Psychiatry (2017)

Howard Liu, SM; Maria V. Petukhova, PhD; Nancy A. Sampson, BA; Sergio Aguilar-Gaxiola, MD, PhD; Jordi Alonso, MD, DrPH; Laura Helena Andrade, MD, PhD; Evelyn J. Bromet, PhD; Giovanni de Girolamo, MD; Josep Maria Haro, MD, PhD; Hristo Hinkov, MD, PhD; Norito Kawakami, MD, DMSc; Karestan C. Koenen, PhD; Viviane Kovess-Masfety, MSc, MD, PhD; Sing Lee, PhD; Maria Elena Medina-Mora, DrPH; Fernando Navarro-Mateu, MD, PhD; Siobhan O’Neill, PsychSc, PhD; Marina Piazza, ScD, MPH; José Posada-Villa, MD; Kate M. Scott, PhD; Victoria Shahly, PhD; Dan J. Stein, FRCPC, PhD; Margreet ten Have, PhD; Yolanda Torres, MPH, DraHC; Oye Gureje, MD, PhD, FRCPsych; Alan M. Zaslavsky, PhD; Ronald C. Kessler, PhD; for the World Health Organization World Mental Health Survey Collaborators
Differential Effects of Insufflated, Subcutaneous, and Intravenous Growth Hormone on Bone Growth, Cognitive Function, and NMDA Receptor Subunit Expression
Authors: Sung Won Park, Sooyoung Shin, Chi Hwa Kim, Ah-ra Ko, Min Jung Kwak, Mi Hyun Nam, So Young Park, Su Jin Kim, Young Bae Sohn, Raymond E. Galinsky, Hojoong Kim, Yoon Yeo, Dong-Kyu Jin
Journal: Endocrine Reviews (2010)
Overview of Reproductive and Developmental Toxicity Studies of 1,3-Butadiene in Rodents
Authors: Richard E. Morrissey, Bernard A. Schwetz, Patricia L. Hackett, Melvin R. Sikov, Bryan D. Hardin, Beatrice J. McClanahan, John R. Decker, Terryl J. Mast
Journal: Environmental Health Perspectives (1990)

A series of studies to further evaluate the developmental and reproductive toxicity of inhaled 1,3-butadiene was sponsored by the National Toxicology Program. Pregnant Sprague-Dawley rats (24-28/group) and Swiss (CD-1) mice (18-22/group) were exposed to atmospheric concentrations of 0, 40, 200, or 1000 ppm 1,3-butadiene for 6 hr/day on days 6 through 15 of gestation (dg) and killed on dg 18 (mice) or dg 20 (rats). Subsequently, the uterine contents were evaluated; individual fetal body weights were recorded; and external, visceral, and skeletal examinations were performed. In rats, maternal toxicity was observed in the 1000-ppm group in the form of reduced extragestational weight gain and, during the first week of treatment, decreased body weight gain. Under these conditions, there was no evidence of developmental toxicity in rats. In contrast, results of the mouse developmental toxicity study indicated that the fetus may be more susceptible than the dam to inhaled 1,3-butadiene. Maternal toxicity was observed in mice at the 200- and 1000-ppm 1,3-butadiene exposure levels, whereas 40 ppm and higher concentrations of 1,3-butadiene caused significant exposure-related reductions in the mean body weights of male fetuses. Mean body weights of female fetuses were also reduced at the 200- and 1000-ppm exposure levels. No increased incidence of malformations was observed in either study. Other studies addressing male reproductive and mutagenesis end points were performed with B6C3F1 mice (sperm-head morphology) and Swiss (CD-1) mice (dominant lethal study).(ABSTRACT TRUNCATED AT 250 WORDS)
Quantifying Estrogen Metabolism: An Evaluation of the Reproducibility and Validity of Enzyme Immunoassays for 2-Hydroxyestrone and 16a-Hydroxyestrone in Urine
Authors: Regina G. Ziegler, Susan C. Rossi, Thomas R. Fears, H. Leon Bradlow, Herman Adlercreutz, Daniel Sepkovic, Paula Kiuru, Kristiina Wahala, Jimmie B. Vaught, Jennifer L. Donaldson, Roni T. Falk, Capri-Mara Fillmore, Pentti K. Siiteri, Robert N. Hoover, Mitchell H. Gail
Journal: Environmental Health Perspectives (1997)
Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"
Authors: Jasmine Zain, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, Savita Dandapani, David Colcher, Nicole Karras, Alex F. Herrera, Amandeep Salhotra, Auayporn P. Nademanee, Ryotaro Nakamura, Eileen P. Smith, Ni-Chun Tsai, David Yamauchi, Kofi Poku, Van Biglang-awa, John E. Shively
Journal: Blood (2018)
Circulating levels of IGF-1 directly regulate bone growth and density
Authors: Shoshana Yakar, Clifford J. Rosen, Wesley G. Beamer, Cheryl L. Ackert-Bicknell, Yiping Wu, Jun-Li Liu, Guck T. Ooi, Jennifer Setser, Jan Frystyk, Yves R. Boisclair, Derek LeRoith
Journal: Journal of Clinical Investigation (2002)

IGF-1 is a growth-promoting polypeptide that is essential for normal growth and development. In serum, the majority of the IGFs exist in a 150-kDa complex including the IGF molecule, IGF binding protein 3 (IGFBP-3), and the acid labile subunit (ALS). This complex prolongs the half-life of serum IGFs and facilitates their endocrine actions. Liver IGF-1–deficient (LID) mice and ALS knockout (ALSKO) mice exhibited relatively normal growth and development, despite having 75% and 65% reductions in serum IGF-1 levels, respectively. Double gene disrupted mice were generated by crossing LID+ALSKO mice. These mice exhibited further reductions in serum IGF-1 levels and a significant reduction in linear growth. The proximal growth plates of the tibiae of LID+ALSKO mice were smaller in total height as well as in the height of the proliferative and hypertrophic zones of chondrocytes. There was also a 10% decrease in bone mineral density and a greater than 35% decrease in periosteal circumference and cortical thickness in these mice. IGF-1 treatment for 4 weeks restored the total height of the proximal growth plate of the tibia. Thus, the double gene disruption LID+ALSKO mouse model demonstrates that a threshold concentration of circulating IGF-1 is necessary for normal bone growth and suggests that IGF-1, IGFBP-3, and ALS play a prominent role in the pathophysiology of osteoporosis.
Die Lagerung verletzter und erkrankter Gliedmassen. Leerschienen und verbandlose Wundbehandlung.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEDICINE AND THE WAR
Journal: JAMA (1946)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PURSUIT OF NOVELTIES IN MEDICINE.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOMESTIC CORRESPONDENCE.
Authors: C.F. Darnall
Journal: JAMA (1892)

<h3>To the Editor of the Journal of the American Medical Association:</h3><h3>Sir:</h3> —Within the past few years the State of Texas has received notice from the profession as possessing a warm, salubrious climate, favorable to that class of patients who are suffering from diseases of the chest, and it may be proper to call attention to the peculiar advantages of Central Texas, or the mountain region. Its elevation is from 1,500 to 2,100 feet above the sea level, over 200 miles from the gulf, and below the thirty-first parallel, so it has a dry, warm, genial, bracing atmosphere. That it is good for nearly all diseases of the pulmonary organs is demonstrated by many a stout individual who came here diseased and is now well. The writer selected Central Texas as having the best advantages for a member of his family, and is well satisfied in his choice. No hectic,
Neurogenic Switching: A Hypothesis for a Mechanism for Shifting the Site of Inflammation in Allergy and Chemical Sensitivity
Authors: William J. Meggs
Journal: Environmental Health Perspectives (1995)

Neurogenic switching is proposed as a hypothesis for a mechanism by which a stimulus at one site can lead to inflammation at a distant site. Neurogenic inflammation occurs when substance P and other neuropeptides released from sensory neurons produce an inflammatory response, whereas immunogenic inflammation results from the binding of antigen to antibody or leukocyte receptors. There is a crossover mechanism between these two forms of inflammation. Neurogenic switching is proposed to result when a sensory impulse from a site of activation is rerouted via the central nervous system to a distant location to produce neurogenic inflammation at the second location. Neurogenic switching is a possible explanation for systemic anaphylaxis, in which inoculation of the skin or gut with antigen produces systemic symptoms involving the respiratory and circulatory systems, and an experimental model of anaphylaxis is consistent with this hypothesis. Food-allergy-iducing asthma, urticaria, arthritis, and fibromyalgia are other possible examples of neurogenic switching. Neurogenic switching provides a mechanism to explain how allergens, infectious agents, irritants, and possibly emotional stress can exacerbate conditions such as migraine, asthma, and arthritis. Because neurogenic inflammation is known to be triggered by chemical exposures, it may play a role in the sick building syndrome and the multiple chemical sensitivity syndrome. Thus neurogenic switching would explain how the respiratory irritants lead to symptoms at other sites in these disorders.
INCREASE OF THE MEDICAL STUDENT CLASS.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1991: Mutant GATA3 actively promotes the growth of normal and malignant mammary cells
Authors: Natasha Chandiramani, Esther Peterson, Paraic A. Kenny
Journal: Cancer Research (2016)

Abstract GATA3 is a transcription factor expressed in luminal breast epithelial cells and is required for mammary gland development. Analysis of TCGA data reveals that somatic heterozygous mutations in GATA3 occur in up to 15% of estrogen receptor positive breast tumors, and that these tumors are diagnosed a median of eight years earlier than other estrogen receptor positive tumors, suggesting a more aggressive phenotype. These mutants have been proposed to be null alleles resulting in haploinsufficiency, however the mutation spectrum of GATA3 in breast cancer is in sharp contrast to that found in HDR syndrome, a true GATA3 haploinsufficiency disease. Based on this disparity, we propose that there is a selective pressure to mutate and retain a portion of the GATA3 in breast cancer. Here we focus on the GATA3 mutants which lack the second zinc finger which is responsible for GATA motif binding. Expression of these mutants accelerated xenograft tumor growth by ZR751 cells, and transgenic expression in mouse mammary glands promoted precocious lobuloalveolar development. We have used integrated gene expression and ChIP-Seq profiling to demonstrate that these zinc-finger deleted proteins retain the ability to associate with the genome by tethering to complexes associated with FOXA1 and AP-2gamma recognition motifs, where they modulate the expression of adjacent genes. These data support a model in which the GATA3 mutations recently observed in breast cancer encode for active transcription factors which elicit proliferative phenotypes in normal mammary epithelium and promote the growth of estrogen receptor positive breast cancer cell lines. Citation Format: Natasha Chandiramani, Esther Peterson, Paraic A. Kenny. Mutant GATA3 actively promotes the growth of normal and malignant mammary cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1991.